RA registriesA Comparison of Patient Characteristics and Outcomes in Selected European and U.S. Rheumatoid Arthritis Registries1
Section snippets
Selection of Registries and Cohorts
While recognizing the existence of numerous RA registries, we identified published articles that report comparable data for the domains described above, with a particular focus on registries and cohorts that allowed for addressing questions related to patient characteristics and comorbidities and the effectiveness, safety, and adherence to biologics used for the treatment of RA. Based largely on size, the European registries selected for this qualitative comparison included the U.K. British
Recruitment Methods and Inclusion Criteria
Table 1 summarizes the governance, nature of data reported, frequency of data collection, and selection criteria of the various cohorts. The European registers initiated by the national rheumatology societies of the respective countries had widely varied inclusion criteria for the biologic and comparator cohorts. The biologic arms generally enroll new users, although new disease-modifying antirheumatic drug (DMARD) use is often not required for the comparator cohorts. U.K. national guidelines
Conclusion
Because results from RCTs may not be generalizable to clinical practice, biologics registries and cohorts have been set up in various countries to bridge the gap in our knowledge regarding the effectiveness and safety of these agents. The large size of these registries and long duration of follow-up allows analysis of rare events, which generally is not possible with RCTs. Our work highlighting the unique features of several of these cohorts points out their various characteristics that may
References (35)
The CORRONA database
Autoimmun Rev
(2006)- et al.
Tumor necrosis factor antagonist responsiveness in a United States rheumatoid arthritis cohort
Am J Med
(2008) - et al.
Veteran's affairs hospital discharge databases coded serious bacterial infections accurately
J Clin Epidemiol
(2007) - et al.
Registries for robust evidence
JAMA
(2009) - et al.
Reduction in the incidence of myocardial infarction in patients with rheumatoid arthritis who respond to anti-tumor necrosis factor alpha therapy: results from the British Society for Rheumatology Biologics Register
Arthritis Rheum
(2007) - et al.
Clinical and functional remission: even though biologics are superior to conventional DMARDs overall success rates remain low—results from RABBIT, the German biologics register
Arthritis Res Ther
(2006) - et al.
The burden of rheumatoid arthritis and access to treatment: uptake of new therapies
Eur J Health Econ
(2008) - et al.
Swedish registers to examine drug safety and clinical issues in RA
Ann Rheum Dis
(2006) - et al.
Anti-tumour necrosis factor therapy in rheumatoid arthritis and risk of malignant lymphomas: relative risks and time trends in the Swedish Biologics Register
Ann Rheum Dis
(2009) - et al.
Clinical quality management in rheumatoid arthritis: putting theory into practiceSwiss Clinical Quality Management in Rheumatoid Arthritis
Rheumatology (Oxford)
(2000)
The effectiveness of anti-tumor necrosis factor therapy in preventing progressive radiographic joint damage in rheumatoid arthritis: a population-based study
Arthritis Rheum
Treatment of rheumatoid arthritis with tumor necrosis factor inhibitors may predispose to significant increase in tuberculosis risk: a multicenter active-surveillance report
Arthritis Rheum
Update III Consensus of the Spanish Society of Rheumatology on biological therapy in rheumatoid arthritis
Reumatol Cl
Patterns of disease modifying antirheumatic drug use in a Spanish cohort of patients with rheumatoid arthritis
J Rheumatol
Risk of serious bacterial infections among rheumatoid arthritis patients exposed to tumor necrosis factor alpha antagonists
Arthritis Rheum
Accuracy of Veterans Administration databases for a diagnosis of rheumatoid arthritis
Arthritis Rheum
Predictors of response to anti-TNF-alpha therapy among patients with rheumatoid arthritis: results from the British Society for Rheumatology Biologics Register
Rheumatology (Oxford)
Cited by (161)
Patient outcomes in longitudinal observational studies (POLOS) of rheumatoid arthritis: Determining the OMERACT core domain set
2024, Seminars in Arthritis and RheumatismAutoantibody-negative rheumatoid arthritis: still a challenge for the rheumatologist
2023, The Lancet RheumatologyPatient perspectives on long-term outcomes in rheumatoid arthritis. A qualitative study from the OMERACT patient outcomes in longitudinal studies working group
2023, Seminars in Arthritis and RheumatismTo treat or not to treat rheumatoid arthritis with glucocorticoids? A reheated debate
2023, Autoimmunity ReviewsChina rheumatoid arthritis registry of patients with Chinese medicine (CERTAIN): Rationale, design, and baseline characteristics of the first 11,764 enrollees
2022, PhytomedicineCitation Excerpt :Thus, it is essential to gain a deeper understanding of CM use by patients with RA using a registry study to test hypotheses of comparative effectiveness or safety, examine the quality of care, and evaluate the safety of CMs for RA patients. Concerns regarding the various uncertainties of RA have facilitated a trend in developing global registries (Curtis et al., 2010; Hyldgaard et al., 2017; Kremer, 2016). China was estimated to have had more than five million RA patients by 2013.
Adipocytokines and achievement of low disease activity in rheumatoid arthritis
2022, Seminars in Arthritis and Rheumatism
The following authors have made disclosures: J.C.: research grants: Amgen, Novartis, UCB, Centocor; consulting: Roche, UCB, CORRONA, Amgen; J.A.: speakers honoraria <$2000 from Wyeth, BMS, Abbott, Centocor, Schering-Plough; A.F.: research grants: Roche, Wyeth; Consulting: Roche, Abbott, Essex, Wyeth; J.L., J.G.: Dr. Greenberg serves as Chief Scientific Officer for CORRONA and has served on Advisory Boards for BMS, Centocor, Genentech, Roche and UCB; A.Z.: research grants: Abbott, Amgen, BMS, Schering-Plough, Roche, UCB, Wyeth; T.M.: research grants: Abbott, Amgen, UCB, (VARA); consulting: UCB; N.S. research grants: Biogen Idec, Crescendo Biosciences, Amgen; M.W. research grants: Biogen Idec, Crescendo Bioscience; consulting: Biogen Idec, Crescendo Bioscience.
All other authors have no conflicts or relevant disclosures.
This work was supported by the Doris Duke Charitable Foundation. Some of the investigators receive support from the National Institutes of Health (AR053351: J.R.C.; AR047782 and AG027066: D.H.S.).
- 1
Authors contributed data from their respective registries and to the editing of the manuscript; aside from the first 2 authors, authors are listed alphabetically.